6505--Carbidopa/Levodopa SA Tablet

The Department of Veterans Affairs National Acquisition Center is seeking proposals for Carbidopa/Levodopa sustained action tablets in two strengths: 25mg/100mg and 50mg/200mg under solicitation number 36E79725R0008. The contract will support VA's standardization program and be distributed through VA and DoD Pharmaceutical Prime Vendor Programs, with authorized users including VA facilities, DoD facilities, Indian Health Service, Bureau of Prisons, Federal Health Care Center, and Option 2 State Veterans Homes. Offerors must provide unique 11-digit NDC numbers, demonstrate FDA approval, maintain cGMP compliance, and if not the manufacturer, submit a Letter of Commitment from the manufacturer. Proposals are due by 2:30 PM CT on January 30, 2025, and must be submitted via email to Christopher.Carthron@va.gov and Diana.Martinez1@va.gov. Pricing must include a 0.5% Cost Recovery Fee, and the implementation period is limited to 60 days maximum.

The solicitation is not set aside for any specific group and will result in one aggregate award with a base year and four one-year options. The estimated annual quantity is 60,932 bottles of the 25mg/100mg strength and 58,943 bottles of the 50mg/200mg strength, with each bottle containing 100 tablets. Authorized users span multiple federal healthcare systems, indicating a broad potential market for the awarded contract. While specific award values are not disclosed, the large volume of tablets suggests a significant procurement opportunity for the successful offeror. The place of performance will involve distribution through the VA and DoD Pharmaceutical Prime Vendor Programs, with products to be made available to the specified authorized users following the 60-day implementation period.